MX2023007192A - Inhibidores de prmt5. - Google Patents

Inhibidores de prmt5.

Info

Publication number
MX2023007192A
MX2023007192A MX2023007192A MX2023007192A MX2023007192A MX 2023007192 A MX2023007192 A MX 2023007192A MX 2023007192 A MX2023007192 A MX 2023007192A MX 2023007192 A MX2023007192 A MX 2023007192A MX 2023007192 A MX2023007192 A MX 2023007192A
Authority
MX
Mexico
Prior art keywords
inhibitors
prmts
compounds
formula
prmt5
Prior art date
Application number
MX2023007192A
Other languages
English (en)
Inventor
Brian Alan Lanman
Liping H Pettus
Patricia Lopez
Nuria A Tamayo
John R Butler
Mikkel Vestergaard
Shon Booker
Matthew Paul Bourbeau
Ian Sarvary
Francesco Manoni
Sanne Omholt Schroder Glad
Nicholas Anthony Weires
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2023007192A publication Critical patent/MX2023007192A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se describen en el presente documento inhibidores novedosos de PRMT5 de Fórmula I y sales farmacéuticamente aceptables de los mismos, así como composiciones farmacéuticas de los mismos. Los compuestos de la presente invención son útiles para inhibir la actividad de PRMT5 y pueden tener uso en el tratamiento de trastornos proliferativos, metabólicos y sanguíneos. Los compuestos de Fórmula I tienen la siguiente estructura: (ver Fórmula).
MX2023007192A 2020-12-16 2021-12-15 Inhibidores de prmt5. MX2023007192A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063126416P 2020-12-16 2020-12-16
PCT/US2021/063540 WO2022132914A1 (en) 2020-12-16 2021-12-15 Prmts inhibitors

Publications (1)

Publication Number Publication Date
MX2023007192A true MX2023007192A (es) 2023-07-03

Family

ID=79927288

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007192A MX2023007192A (es) 2020-12-16 2021-12-15 Inhibidores de prmt5.

Country Status (17)

Country Link
US (2) US11845760B2 (es)
EP (1) EP4263545A1 (es)
JP (2) JP7487421B2 (es)
KR (1) KR20230121820A (es)
CN (1) CN116888120A (es)
AR (1) AR124369A1 (es)
AU (1) AU2021400942A1 (es)
CA (1) CA3204823A1 (es)
CL (1) CL2023001738A1 (es)
CO (1) CO2023008167A2 (es)
CR (1) CR20230310A (es)
IL (1) IL303451A (es)
MX (1) MX2023007192A (es)
PE (1) PE20231295A1 (es)
TW (1) TW202233183A (es)
UY (1) UY39565A (es)
WO (1) WO2022132914A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
EP4188920A1 (en) 2020-07-31 2023-06-07 Tango Therapeutics, Inc. Piperidin-1-yl-n-pyrydine-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers
MX2024002589A (es) * 2021-08-30 2024-04-30 Amgen Inc Proceso para sintetizar derivados de naftiridina y compuestos intermedios de los mismos.
WO2023196545A1 (en) * 2022-04-08 2023-10-12 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
WO2024002263A1 (zh) * 2022-06-30 2024-01-04 南京明德新药研发有限公司 氨基取代的杂芳基衍生物及其应用
WO2024002377A1 (zh) * 2022-07-01 2024-01-04 上海赛岚生物科技有限公司 一类prmt5抑制剂及其用途
WO2024021957A1 (zh) * 2022-07-26 2024-02-01 上海和誉生物医药科技有限公司 一种prmt5抑制剂及其制备方法和药学上的应用
WO2024027370A1 (zh) * 2022-08-03 2024-02-08 上海和誉生物医药科技有限公司 一种含氮三稠环prmt5抑制剂，其制备方法和药学上的用途
WO2024038004A1 (en) 2022-08-15 2024-02-22 Astrazeneca Ab Mta-cooperative prmt5 inhibitors for use in the treatment of cancer
WO2024037459A1 (zh) * 2022-08-18 2024-02-22 南京明德新药研发有限公司 含酰胺的杂环衍生物及其应用
CN117658980A (zh) * 2022-09-08 2024-03-08 郑州同源康医药有限公司 双环类prmt5抑制剂
WO2024067445A1 (zh) * 2022-09-26 2024-04-04 上海湃隆生物科技有限公司 新型prmt5抑制剂及其应用
CN115677708A (zh) * 2022-10-19 2023-02-03 五邑大学 一种吡咯并喹喔啉的制备方法
WO2024118897A1 (en) * 2022-11-30 2024-06-06 Amgen Inc. Cancer treatments using a prmt5 inhibitor and a mat2a inhibitor
WO2024123740A1 (en) * 2022-12-05 2024-06-13 Amgen Inc. Solid forms of naphthyridine compounds
WO2024131901A1 (zh) * 2022-12-23 2024-06-27 深圳微芯生物科技股份有限公司 一类含炔基取代的杂环酰胺衍生物、其制备方法及其应用
WO2024153128A1 (en) * 2023-01-18 2024-07-25 Shanghai Antengene Corporation Limited Prmt5 inhibiting compounds and uses thereof
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy
WO2024182466A1 (en) * 2023-02-28 2024-09-06 Amgen Inc. Process for synthesizing naphthyridine derivatives and intermediates thereof
CN118221682A (zh) * 2023-05-17 2024-06-21 四川科伦博泰生物医药股份有限公司 酰胺化合物、包含其的药物组合物及其制备方法和用途
US11845749B1 (en) 2023-07-13 2023-12-19 King Faisal University Substituted pyrido[4′,3′:5,6]pyrazino[1,2-a]indoles as anticancer agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106573932B (zh) 2014-08-22 2019-07-30 默克专利股份公司 吲唑类
UA126481C2 (uk) 2017-08-09 2022-10-12 Прел'Юд Терап'Ютікс, Інкорпорейтід Селективний інгібітор протеїнової аргінінметилтрансферази 5 (prmt5)
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
JP2023513580A (ja) * 2020-02-12 2023-03-31 アムジェン インコーポレイテッド 新規ｐｒｍｔ５阻害剤

Also Published As

Publication number Publication date
JP2024102236A (ja) 2024-07-30
US20240092794A1 (en) 2024-03-21
US11845760B2 (en) 2023-12-19
AR124369A1 (es) 2023-03-22
WO2022132914A1 (en) 2022-06-23
JP2023550530A (ja) 2023-12-01
JP7487421B2 (ja) 2024-05-20
IL303451A (en) 2023-08-01
TW202233183A (zh) 2022-09-01
CO2023008167A2 (es) 2023-07-21
CL2023001738A1 (es) 2023-11-17
UY39565A (es) 2022-06-30
CR20230310A (es) 2023-09-01
KR20230121820A (ko) 2023-08-21
PE20231295A1 (es) 2023-08-22
AU2021400942A1 (en) 2023-07-06
US20220194955A1 (en) 2022-06-23
CN116888120A (zh) 2023-10-13
CA3204823A1 (en) 2022-06-23
EP4263545A1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
MX2023007192A (es) Inhibidores de prmt5.
MX2022010011A (es) Inhibidores de prmt5 novedosos.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
CR20230286A (es) Inhibidores de prmt5 novedosos
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
CR20220230A (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
AU2011297889A8 (en) Pharmaceutically active compounds as Axl inhibitors
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
EA201991916A1 (ru) 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2021014372A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
JOP20220227A1 (ar) مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
CR20220538A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
MX2024004444A (es) Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).
MX2023013683A (es) Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
MX2022013482A (es) Compuestos utiles para inhibir la quinasa ret.
MX2022004878A (es) Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.
NZ777925A (en) Deoxy- cytidine or uridine derivatives for use in cancer therapies